Topic summary

Historical amylin analogues and what happened to them

Compounds › Cagrilintide & amylin analogues randomised trial cagrilintide cagrisema effect size amylin analogues

This is a generated summary. It shows the 5 most-liked posts from a topic of 37, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

e.iyerTL2 Moderator21 Apr 2026#2

Worth separating two things that the opening post runs together.

Amylin signalling is distinct from GLP-1 signalling. Amylin slows gastric emptying and promotes satiety through a different receptor and different neural pathways. The hypothesis behind combination is two complementary satiety mechanisms with one injection.

23 likes 3mo

k.dahlbergTL2 Moderator7 May 2026#6

On post #2 — agreed on the reasoning, with one qualification.

The dosing interval: cagrilintide's half-life is roughly 7 to 8 days, suitable for weekly dosing. The pharmacokinetics are the reason the dosing schedule makes sense.

31 likes 3mo

a.schaefferTL2Member14 Jun 2026#19

The dosing interval: cagrilintide's half-life is roughly 7 to 8 days, suitable for weekly dosing. The pharmacokinetics are the reason the dosing schedule makes sense.

28 likes 1mo

KnowltonTL3Regular29 Jun 2026#25

For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.

25 likes 29d

ms_hollowayTL4Mass spectrometrist20 Jul 2026#34

This follows post #31 rather than contradicting it.

Gastric emptying: both amylin and GLP-1 slow it, through partly overlapping but distinct mechanisms. Whether the slowing at a higher magnitude produces disproportionate nausea or is tolerable is a question phase 3 exists to answer.

25 likes 8d

Read the full topic (37 posts)

Suggested topics

Topic	Participants	Replies	Views	Activity
The CagriSema phase 2 paper and what a fixed combination buys — the long version Compounds › Cagrilintide & amylin analogues amylin analogues cagrisema cagrilintide The CagriSema phase 2 paper and what a fixed combination buys — the long version Writing it up because I had to work it out twice and would rather nobody else did. I have seen STEP 1 ( N Engl J Med , 2021)…	+137	158	17k	13mo
Is "synergy" the right word for the combination data? Compounds › Cagrilintide & amylin analogues randomised trial cagrilintide effect size Is "synergy" the right word for the combination data? — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SCALE ( N Engl J Med , 2015). Please read it…	+5	9	13k	25d
Coming back to: Amylin analogue mechanism: satiety signalling separate from GLP-1 Compounds › Cagrilintide & amylin analogues cagrisema effect size randomised trial cagrilintide On the subject in the title: Amylin analogue mechanism: satiety signalling separate from GLP-1 Working notes rather than a conclusion. I have seen SELECT ( N Engl J Med , 2023) cited in support of a claim I…	+27	31	671	12mo
Cagrilintide's dosing interval and the pharmacokinetics behind it Compounds › Cagrilintide & amylin analogues effect size randomised trial amylin analogues cagrisema Solved Cagrilintide's dosing interval and the pharmacokinetics behind it — setting out what I have, and where I think it stops being reliable. Comparing LEADER ( N Engl J Med , 2016) with SELECT ( N Engl J Med ,…	+98	105	24k	10mo
Reading a combination trial: attributing effect to components Compounds › Cagrilintide & amylin analogues cagrisema amylin analogues effect size cagrilintide Closed On the subject in the title: Reading a combination trial: attributing effect to components Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before…		4	19k	11mo

Related topics — sharing the tags randomised trial, cagrilintide, cagrisema

Topic	Participants	Replies	Views	Activity
Dose numbers for oral formulations are not comparable to injectable ones — a second dataset Compounds › Oral incretins randomised trial orforglipron PIONEER programme Dose numbers for oral formulations are not comparable to injectable ones — a second dataset Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SUSTAIN 6 ( N Engl…	+48	52	59k	18mo
Primary endpoint hierarchies and why order matters Evidence › Trials randomised trial intention to treat estimand Primary endpoint hierarchies and why order matters Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURMOUNT-OSA ( N Engl J Med , 2024) with SURPASS-2 ( N Engl J…		4	308	3mo
Follow-up: Open-label extensions: what survives and what does not Evidence › Trials open label intention to treat surrogate endpoints estimand Solved Open-label extensions: what survives and what does not — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with SURMOUNT-1 ( N Engl J Med , 2022) and…	+22	26	397	16mo
How to read a phase 2 result without treating it as a phase 3 result — what changed since Compounds › Retatrutide TRIUMPH programme randomised trial preprint Solved Asking directly, because I could not find a straight answer: How to read a phase 2 result without treating it as a phase 3 result — what changed since Session topic: STEP 2 ( Lancet , 2021). Please read it…	+25	35	568	6mo
Tirzepatide storage and stability: what is published versus what is assumed — does this still hold? Compounds › Tirzepatide tirzepatide SURPASS programme effect size The question in the title: Tirzepatide storage and stability: what is published versus what is assumed — does this still hold? I will give what I have already checked below so nobody repeats it. Comparing…	+15	19	930	18mo